Keywords: MacroGenics, Gilead Sciences, Worldwide rights, DART products, Antibody platform

MacroGenics in deal potentially worth $1 billion with Gilead for DART products

Article | 09 January 2013

Print This

Privately held US biotech firm MacroGenics has entered into a license agreement with Gilead Sciences (Nasdaq: GILD) for the development ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in